(Q35039488)

5 August 2017

1 reference

title

The use of bisphosphonates in patients with breast cancer (English)

1 reference

5 August 2017

author name string

Catherine H Van Poznak

series ordinal

1

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

480-489

1 reference

5 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

The clinical course of bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Identifying breast cancer patients at high risk for bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Molecular basis of the spectrum of skeletal complications of neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Recent advances: palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Management of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Osteoporosis due to cancer treatment: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900605

10.1177/107327480200900605

21 January 2018

Identifiers

DOI

0 references

Fatcat ID

release_i54h3r5nmjgtrohazi2634rhrm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i54h3r5nmjgtrohazi2634rhrm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference